Karl, Martin; Hasselwander, Solveig; Zhou, Yawen et al.
Dual roles of B lymphocytes in mouse models of diet-induced nonalcoholic fatty liver diseaseHEPATOLOGY. 2022
Czysch, Christian; Medina-Montano, Carolina; Dal, Nils-Jorgen Knudsen et al.
End Group Dye-Labeled Polycarbonate Block Copolymers for Micellar (Immuno-)Drug DeliveryMACROMOLECULAR RAPID COMMUNICATIONS. 2022
Schmitt, Sascha; Huppertsberg, Anne; Klefenz, Adrian et al.
Fluorescence Correlation Spectroscopy Monitors the Fate of Degradable Nanocarriers in the Blood StreamBIOMACROMOLECULES. 2022
Schuppan, Detlef; Myneni, Sudharani; Surabattula, Rambabu
Liquid biomarkers for fibrotic NASH - progress in a complex fieldJOURNAL OF HEPATOLOGY. Bd. 76. H. 1. 2022 S. 5-7
Kaps, Leonard; Huppertsberg, Anne; Choteschovsky, Niklas et al.
pH-degradable, bisphosphonate-loaded nanogels attenuate liver fibrosis by repolarization of M2-type macrophagesPROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. Bd. 119. H. 12. 2022
Schuppan, D
: Can Plant Materials Be Valuable in the Treatment of Periodontal Diseases?Pharmaceutics. Bd. 13. 2021 S. 2185
Crouchet, Emilie; Bandiera, Simonetta; Fujiwara, Naoto et al.
A human liver cell-based system modeling a clinical prognostic liver signature for therapeutic discoveryNATURE COMMUNICATIONS. Bd. 12. H. 1. 2021
Villesen, Ida; Langholm, Lasse; Leeming, Diana et al.
A novel liver-specific fibrosis biomarker, PRO-C18L, can predict response to antifibrotic treatment, with a peroxisome proliferator activated receptor -y agonist, in patients with chronic hepatitis CJOURNAL OF HEPATOLOGY. Bd. 75. 2021 S. S633-S633
Schuppan, Detlef; Maki, Markku; Lundin, Knut E. A. et al.
A randomized trial of a transglutaminase 2 inhibitor for celiac diseaseNEW ENGLAND JOURNAL OF MEDICINE. Bd. 385. H. 1. 2021 S. 35-45
Schuppan, D
A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosisJ Hepatology. 2021 S. 816